Sentences with phrase «patient differences between groups»

The researchers adjusted for multiple variables, including a propensity score reflecting the probability of receiving bivalirudin to account for patient differences between groups.

Not exact matches

There were no differences between groups in parity, incidence of diabetes, operative delivery, or third - degree compared with fourth - degree lacerations.By 2 weeks postpartum, patients who received prophylactic antibiotics at the time of third - or fourth - degree laceration repair had a lower rate of perineal wound complications than patients who received placebo.ClinicalTrials.gov, www.clincaltrials.gov, NCT00186082.I.

Researchers report that the only substantial difference in safety outcomes between the placebo and bococizumab groups was injection site reactions, which is also the result of the immunologic response in some patients.

While stromal ADC and sonographic cervical length showed no difference between both groups, the subglandular ADC was higher in patients with impending delivery, suggesting an increased mobility of water molecules in that area consistent with cervical ripening.

«Patients undergoing surgery for a hip fracture were older and had more comorbidities than patients who underwent an elective THR, and these differences accounted for some of the difference in outcomes between these groups,» the authorPatients undergoing surgery for a hip fracture were older and had more comorbidities than patients who underwent an elective THR, and these differences accounted for some of the difference in outcomes between these groups,» the authorpatients who underwent an elective THR, and these differences accounted for some of the difference in outcomes between these groups,» the authors write.

A follow - up of the 48 patients who were evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.

The survival difference between the two groups was not statistically significant, but investigators said the results point to a possible benefit of GO treatment for some pediatric AML patients whose cancer remained following chemotherapy.

Others have speculated that, by being involved in a clinical trial, patients in both arms of the trial received better care than they would otherwise have done, obfuscating any differences between the groups.

The authors hypothesized that differences would exist between age groups, with younger patients having a larger number of symptoms, greater severity of symptoms, and increased time to return to baseline after sustaining a concussion.

In his book, The Cholesterol Myths: Exposing the Fallacy That Saturated Fat and Cholesterol Cause Heart Disease, Swedish physician Uffe Ravnskov asserts that as of 1998, 27 studies on diet and heart disease had been published regarding 34 groups of patients; in 30 of those groups investigators found no difference in animal fat consumption between those who had heart disease and those who did not.

«While most studies show there are no significant differences in clinical response between a biosimilar and the original product, some physicians and patient advocacy groups have expressed concern about how interchangeable they really are, and whether it is safe to switch from the brand name version to the biosimilar,» said lead author Dr Daniel Nagore of Progenika Biopharma, Derio, Spain.

For the subsequent three years, there was no longer a significant difference between the two groups in the number of patients who required surgical treatment for an SCC.

During the nearly month - long follow - up period, there were no differences between the two groups in the percentages of patients that had a stent placed to open an artery, underwent coronary artery bypass surgery, returned to the emergency room or experienced a major cardiac event, such as heart attack.

The study found no significant differences between patients in both groups.

A major clinical trial randomizing patients to either initial surgery followed by chemotherapy, or chemotherapy then surgery, revealed no significant difference in overall survival between the groups.

But those differences were found mostly in the biopsy samples; there weren't many differences between the feces from Crohn's patients and the control group.

Although there was no significant difference between the two groups in breast shrinkage, breast oedema, breast induration (hardening), and pigmentation changes, the benefits of using IMRT in these patients were clear.

However, these studies tended to lack long - term follow - up, evaluated limited patient numbers, had differences in medication after surgery between both groups and lacked the data on cause of death that are needed to evaluate breast cancer - specific survival.

Dividing patients into three groups — those receiving high, medium and low FFP to RBC ratio transfusions — revealed no difference in 30 - day mortality between groups, including for trauma patients.

In contrast to the neutrophil analyses, two groups reported no detectable differences between the mitochondrial complex activities they assayed in peripheral blood mononuclear cells (PBMCs) of ME / CFS patients vs. controls [6, 7].

Also, we aim to look at structural differences within the patient group, for example between patients with and without comorbid depression.

No significant difference was seen between the groups of patients in risk for intracranial bleeding (Table 2).

Differences in DRRs between groups were smaller for stage IV patients (11 % for T - VEC, 7 % for GM - CSF).

However, no statistically significant difference was seen in 2 - year PFS between patients in the intermediate - and high - risk groups.

Given that ovulatory dysfunction is a key feature of PCOS, one group investigated a cohort of PCOS patients to determine if there was an association with this polymorphism.68 They reported significant differences in the genotype distribution and allelic frequencies between controls and PCOS patients that supported a correlation with the G / A polymorphism.68 To date, the underlying mechanism has not been established.

There was no difference in the production, uptake, oxidation and metabolism of glutamine between the control group and the patients with Crohn's disease.

Although we observed no difference between groups in terms of glycosylated hemoglobin levels, this may be because the patients» primary physicians were free to decrease the number or dosage of hypoglycemic medications in response to lower glycemia.

We entered the number of patients and control group members, mean age, percentage of girls and of members of ethnic minorities, the country of data collection, year of publication, type of illness, duration of illness, the sampling procedure (1 = probability samples, 0 = convenience samples), the use of a control group (0 = yes, 1 = comparison with test norms), equivalence of patients and control group (1 = yes, 2 = not tested, 3 = no), the rater of depressive symptoms (1 = child, 2 = parent, 3 = teacher, 4 = clinician), the measurement of the variables, and the standardized size of between - group differences in depressive symptoms.

Post hoc analysis revealed two significant differences in between - group comparisons: patients with schizophrenia versus healthy controls (estimated mean ± standard error; 30.05 ± 1.95 vs. 38.57 ± 2.22, corrected p = 0.040) and patients with bipolar disorder versus healthy controls (28.80 ± 1.78 vs. 38.57 ± 2.22, corrected p = 0.006)(Fig. 1).

Post hoc analysis revealed a significant difference in the between - group comparisons: patients with bipolar disorder versus healthy controls (20.30 ± 1.89 vs. 30.27 ± 2.35, corrected p = 0.009)(Fig. 1).

Moreover, men with depressive symptoms have reduced parasympathetic activity compared with control subjects, whereas no differences between depressed women and controls have been reported.44) Because the demographic characteristics of patients with various psychiatric disorders (e.g., schizophrenia, bipolar disorder, PTSD, and MDD) differ, the recruitment of separate groups of healthy controls that are well matched to individuals with each psychiatric disorder is necessary to clarify the HRV data.

Parameters were calculated from a 30 min ECG recording, with SD of R — R interval (SDNN), low frequency (LF) power and high frequency (HF) power found to be lower in the BD group.17 In 2012, Levy used several physiological measures of autonomic nervous system function to determine differences between patients with BD and healthy controls, without using the traditional HRV features.

Post hoc analysis revealed a significant difference in between - group comparisons: patients with bipolar disorder versus healthy controls (163.04 ± 35.99 vs. 335.48 ± 44.70, corrected p = 0.025)(Fig. 2).

This difference was significant when the number of patients who showed a 50 % or greater improvement was compared between those who received cognitive behaviour therapy and the other two groups combined (χ2 = 3D5.18; df = 3D1; P = 3D0.02).

There were no significant differences between patients in both placebo and fluoxetine groups on measures of general psychiatric symptoms, global functioning or self - reported depressive symptom measurements (Moldenhauer & Melnyk, 1999).

Difference in outcome between the two patient groups were not significant.

The percentage of patients reporting a reduction in those illness beliefs and coping behaviours previously found to be associated with poor outcome (strong belief in a physical cause or persistent viral infection and extreme avoidance of exercise) 10 13 14 between baseline and the end of treatment was calculated in each treatment group and the significance of the difference determined by χ2 test.

Despite this, the final sample size with 180 patients being randomised was sufficiently powered to detect differences between the groups.

To examine possible differences in correlations between caregiver burden and EE across patient groups.